Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Likely Not 'Significant', Could Be Mostly Spared From Trump's Regulation-Slashing Order

Executive Summary

But even though executive order that requires regulatory off sets may only have limited application to FDA, limited, experts warn that it still could prove extremely unwieldly to implement.


Related Content

US FDA Faces Down Complex Combo Products, Fires Up Oncology Center Of Excellence
FDA Tussles With Combination Products, Fires Up Oncology Center Of Excellence
FDA Getting Reg Slashing Directive In Trump Executive Order
Ostroff: Administration Coming Up To Speed On Planned FDA Guidances
Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support
FDA Claims Sole Authority Over Naming Of US-Licensed Biologics
Trump Order Reducing Regulation Might Imperil FDA Good Guidance Practices
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Generic Labeling Rule Becomes Statistical Battle As Public Meeting Looms
Generic Labeling Rule Delays Mount





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts